SHR 7390

Drug Profile

SHR 7390

Alternative Names: SHR7390

Latest Information Update: 06 Jun 2017

Price : $50

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Class Antineoplastics
  • Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 14 Jun 2017 Jiangsu HengRui Medicine plans a phase I trial for Solid tumours (Late-stage disease, Combination therapy) in China (NCT03182673)
  • 16 Nov 2016 Jiangsu HengRui Medicine plans a phase I trial for Solid tumours (In adults; In the elderly; Late-stage disease) in China (NCT02968485)
  • 01 Nov 2016 Phase-I clinical trials in Solid tumours (In adults, In the elderly, Late-stage disease) in China (PO) (NCT02968485)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top